|
|
|
|
June 2009 Briefing - Cardiology
Here are what the editors at HealthDay consider to be the most important developments in Cardiology for June 2009.This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes...
|
|
|
June 2009 Briefing - Pediatrics
Here are what the editors at HealthDay consider to be the most important developments in Pediatrics for June 2009.This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes...
|
|
|
Human cardiac master stem cells identified
What is truly groundbreaking about the study, and has enormous implications in terms of the future treatment of heart disease, Kenneth Chien says, is that the study provides a new way of understanding heart disease at it appears...
|
|
|
Survival Good in Transplant for Congenital Heart Disease
TUESDAY, June 30 (HealthDay News) -- In heart transplant patients, those who are transplanted for congenital heart disease and survive the early postoperative period are usually as likely as other patients to experience late...
|
|
|
Prenatal Detection of Congenital Heart Disease
(Click the title below to leave the MDLinx Network and go to the Journal's Website) The Journal of Pediatrics, 06/30/09 Print Save in My Library Free Abstract Friedberg MK et al.- Prenatal detection of major CHD significantly alters...
|
|
|
Congenital Disseminated Pyogenic Granuloma
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Pediatric Dermatology, 06/26/09 Print Save in My Library Free Abstract Browning JC et al.- In the past pyogenic granuloma (PG) in infancy has been easily...
|
|
|
Research Report: HIV protein shell structure revealed
New research by scientists at The Scripps Research Institute (TSRI) and other institutions provides a close-up look at the cone-shaped shell that is the hallmark of human immunodeficiency virus (HIV).The genetic material within HIV is...
|
|
|
Congenital absence of portal vein associated with nodular regenerative hyperplasia of the liver and pulmonary
Langford Lane, Kidlington Oxford.OX5 1GB UK Tel: +44 (0) 1865-843177 (Within Europe) Fax: +44 (0) 1865-843970 E-mail: eurosupport@elsevier.com North American and Rest of World Online Customer Service 6277 Sea Harbor Drive Orlando. ...
|
|
|
RNASET2-deficient cystic leukoencephalopathy resembles congenital cytomegalovirus brain infection
Congenital cytomegalovirus brain infection without symptoms at birth can cause a static encephalopathy with characteristic patterns of brain abnormalities.Here we show that loss-of-function mutations in the gene encoding the RNASET2...
|
|
|
Cytomegalovirus Blood Viral Load and Hearing Loss in Young Children With Congenital Infection
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Pediatric Infectious Disease Journal, 06/24/09 Print Save in My Library Free Abstract Ross SA et al.- Peripheral blood viral load is not associated...
|
|
|
US FDA grants paediatric exclusivity for The Medicines Company's Angiomax
The Medicines Company announced that the US Food and Drug Administration (FDA) has granted paediatric exclusivity for Angiomax (bivalirudin), based on studies submitted in response to a Written Request by the FDA to investigate the use of...
|
|
|
Targeted Genetics Announces Continued Clinical Study at University College London/Moorfields Eye Hospital for
Targeted Genetics Corporation ( NASDAQ:TGEN) today announced that its collaborator at the University College London/Moorfields Eye Hospital (UCL/M) has begun the next step in its Phase 1/2 dose escalation clinical trial to treat a form of...
|
|
|
Targeted Genetics Announces Continued Clinical Study at University College London/Moorfields Eye Hospital for
SEATTLE, WA -- (MARKET WIRE) -- 06/22/09 -- Targeted Genetics Corporation (NASDAQ: TGEN) today announced that its collaborator at the University College London/Moorfields Eye Hospital (UCL/M) has begun the next step in its Phase 1/2 dose...
|
|
|
Targeted Genetics Cuts Workforce in Half in Bid to Survive Into August
Targeted Genetics, the Seattle-based developer of gene therapies, said today it is cutting more than half of its workforce in a bid to make its dwindling cash reserves last into August.The company (NASDAQ: TGEN) said it will cut its staff...
|
|
|
Targeted Genetics Announces Continued Clinical Study at University College London/Moorfields Eye Hospital for
Targeted Genetics Announces Continued Clinical Study at University College London/Moorfields Eye Hospital for a Gene Therapeutic to Treat Leber's Congenital Amaurosis and Provides Business Updat More News related to TGEN More News...
|
|
|
Targeted Genetics Announces Continued Clinical Study at University College London/Moorfields Eye Hospital for
Targeted Genetics Corporation (NASDAQ: TGEN) today announced that its collaborator at the University College London/Moorfields Eye Hospital (UCL/M) has begun the next step in its Phase 1/2 dose escalation clinical trial to treat a form of...
|
|
|
Targeted Genetics Announces Continued Clinical Study at University College London/Moorfields Eye Hospital for
Targeted Genetics Corporation (NASDAQ: TGEN) today announced that its collaborator at the University College London/Moorfields Eye Hospital (UCL/M) has begun the next step in its Phase 1/2 dose escalation clinical trial to treat a form of...
|
|
|
Targeted Genetics Announces Continued Clinical Study at University College London/Moorfields Eye Hospital for
(MARKETWIRE via COMTEX) -- TGEND | Quote | Chart | News | PowerRating -- Targeted Genetics Corporation (NASDAQ: TGEN | Quote | Chart | News | PowerRating) today announced that its collaborator at the University College London/Moorfields Eye...
|
|
|
Targeted Genetics Announces Continued Clinical Study at University College London/Moorfields Eye Hospital for
More News related to TGEN More News related to Press Releases SEATTLE, WA -- (MARKET WIRE) -- 06/22/09 -- Targeted Genetics Corporation (NASDAQ: TGEN) today announced that its collaborator at the University College London/Moorfields Eye...
|
|
|
Targeted Genetics Announces Continued Clinical Study at
Targeted Genetics Corporation (NASDAQ: TGEN) today announced that its collaborator at the University College London/Moorfields Eye Hospital (UCL/M) has begun the next step in its Phase 1/2 dose escalation clinical trial to treat a form of...
|
|
|
Targeted Genetics Announces Continued Clinical Study at University College London/Moorfields Eye Hospital for
2009-06-2207:30ET - News Release SEATTLE, WA -- (MARKET WIRE) -- 06/22/09 Targeted Genetics Corporation (NASDAQ: TGEN) today announced that its collaborator at the University College London/Moorfields Eye Hospital (UCL/M) has begun the next...
|
|
|
Targeted Genetics Announces Continued Clinical Study at University College London/Moorfields Eye Hospital for
Targeted Genetics Corporation (NASDAQ: TGEN) today announced that its collaborator at the University College London/Moorfields Eye Hospital (UCL/M) has begun the next step in its Phase 1/2 dose escalation clinical trial to treat a form of...
|
|
|
Pregnancy and Estrogen Receptor beta Expression in a Large Congenital Nevus
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3.Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. Pregnancy and...
|
|
|
Targeted Genetics cuts staff in survival effort
Seattle-based Targeted Genetics is hunkering down into survival mode as it works through an 11th-hour effort to save the company.The developer is cutting its workforce from 35 down to 10 to 15, renegotiating a lease in Bothell, WA and...
|
|
|
CYP21A2 Mutation Analysis Shows No Genotype-Phenotype Correlation in Adults With Congenital Adrenal Hyperplasi
-- In adults with congenital adrenal hyperplasia (CAH), no significant associations exist between genotype and physical characteristics, as shown by a genetic analysis presented here at the Endocrine Society's 91st Annual Meeting (ENDO 09)....
|
